GLAXF — GSK plc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1131399 ·
United Kingdom
Last close
$25.31
Market Cap
$101.38B
52W High
$27.40
52W Low
$23.46
ADV30
770
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 7,629,000,000 | 5,754,000,000 | 2,293,000,000 | 1,737,000,000 | 62,869,000,000 | 3,442,000,000 | 45,447,000,000 |
| Dec 2025 | 8,618,000,000 | 5,961,000,000 | 1,506,000,000 | 636,000,000 | 61,118,000,000 | 3,150,000,000 | 45,162,000,000 |
| Sep 2025 | 8,547,000,000 | 6,289,000,000 | 2,593,000,000 | 2,013,000,000 | 61,339,000,000 | 3,296,000,000 | 45,587,000,000 |
| Jun 2025 | 7,986,000,000 | 5,821,000,000 | 2,023,000,000 | 1,443,000,000 | 59,258,000,000 | 3,599,000,000 | 44,904,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$7,737,000,000
Investing CF
$-4,555,000,000
Financing CF
$-4,271,000,000
CapEx
$-2,980,000,000
Dividends Paid
$-2,595,000,000
Buybacks
$-1,456,000,000
EPS Diluted TTM
$1.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$11,590,000,000
Inventory
$6,157,000,000
Receivables
—
ST Investments
$1,000,000
EBIT TTM
$8,129,000,000
Pretax Income TTM
$7,437,000,000
Interest Exp TTM
$692,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,779,999,232
EBITDA
$11,432,999,936
Free Cash Flow
$3,019,249,920
Enterprise Value
$116,993,236,992
Total Cash
$3,443,000,064
Total Debt
$19,111,999,488
Shares Out
4,005,595,364
Trailing EPS
$1.90
Book Value
$5.96
ROE
40.9%
ROA
10.0%
Div Yield
3.55%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,667,000,000 | 8,338,000,000 | 5,716,000,000 | 61,118,000,000 | 45,162,000,000 | — | 7,741,000,000 |
| Dec 2024 | 31,376,000,000 | 5,542,000,000 | 2,575,000,000 | 59,463,000,000 | 46,377,000,000 | — | 6,554,000,000 |
| Dec 2023 | 30,328,000,000 | 7,345,000,000 | 4,928,000,000 | 59,005,000,000 | 46,210,000,000 | — | 6,768,000,000 |
| Dec 2022 | 29,324,000,000 | 6,729,000,000 | 14,956,000,000 | 60,146,000,000 | 50,050,000,000 | — | 7,403,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GSK | GSK plc | $102.84B | $51.35 | — |
| SNY | Sanofi | $103.77B | $43.35 | — |
| SNYNF | Sanofi | $105.66B | $88.28 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $121.16B | $477.36 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $126.79B | $62.09 | — |
News headlines (Yahoo Finance, 1h cache)
Top Research Reports for Intel, Dell & Progressive
2026-07-24 20:41 · Yahoo
GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval
2026-07-24 10:09 · Yahoo
GSK (LSE:GSK) Could Be 10% Undervalued On Jideytro FDA Approval
2026-07-24 09:07 · Yahoo
GSK (LSE:GSK) Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance
2026-07-24 01:10 · Yahoo
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
2026-07-23 18:16 · Yahoo
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
2026-07-23 14:33 · Yahoo
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
2026-07-23 14:31 · Yahoo
Will GSK's Specialty Medicines Boost Q2 Revenue Growth?
2026-07-23 13:08 · Yahoo
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
2026-07-22 17:58 · Yahoo
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
2026-07-22 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.